# Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

> **NCT03854110** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Geistlich Pharma AG** · enrollment: 64 (estimated)

## Conditions studied

- Pancreatic Cancer, Adult

## Interventions

- **DRUG:** GP-2250

## Key facts

- **NCT ID:** NCT03854110
- **Lead sponsor:** Geistlich Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-14
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854110, "Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03854110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*